Demetri GD - Search Results

1

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Joensuu H, et al. Among authors: demetri gd. N Engl J Med. 2001 Apr 5;344(14):1052-6. doi: 10.1056/NEJM200104053441404. N Engl J Med. 2001. PMID: 11287975 Free article. No abstract available.

2

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. Tuveson DA, et al. Among authors: demetri gd. Oncogene. 2001 Aug 16;20(36):5054-8. doi: 10.1038/sj.onc.1204704. Oncogene. 2001. PMID: 11526490

3

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Demetri GD. Demetri GD. Semin Oncol. 2001 Oct;28(5 Suppl 17):19-26. Semin Oncol. 2001. PMID: 11740803 Review.

4

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Demetri GD, et al. N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461. N Engl J Med. 2002. PMID: 12181401 Free article. Clinical Trial.

5

Management of malignant gastrointestinal stromal tumours.

Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Joensuu H, et al. Lancet Oncol. 2002 Nov;3(11):655-64. doi: 10.1016/s1470-2045(02)00899-9. Lancet Oncol. 2002. PMID: 12424067 Review.

6

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.

Demetri GD. Demetri GD. Hematol Oncol Clin North Am. 2002 Oct;16(5):1115-24. doi: 10.1016/s0889-8588(02)00052-7. Hematol Oncol Clin North Am. 2002. PMID: 12512386 Review.

7

Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

Demetri GD. Demetri GD. Eur J Cancer. 2002 Sep;38 Suppl 5:S52-9. doi: 10.1016/s0959-8049(02)80603-7. Eur J Cancer. 2002. PMID: 12528773 Review.

8

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Heinrich MC, et al. Among authors: demetri gd. J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190. J Clin Oncol. 2003. PMID: 14645423 Clinical Trial.

9

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD, Joensuu H. Bono P, et al. Among authors: demetri gd. Blood. 2004 Apr 15;103(8):2929-35. doi: 10.1182/blood-2003-10-3443. Epub 2004 Jan 8. Blood. 2004. PMID: 15070666 Free article. Clinical Trial.

10

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass.

Demetri GD, Titton RL, Ryan DP, Fletcher CD. Demetri GD, et al. N Engl J Med. 2004 Oct 21;351(17):1779-87. doi: 10.1056/NEJMcpc049024. N Engl J Med. 2004. PMID: 15496628 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results